Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00147303
Status:
COMPLETED
Last Update Posted:
2015-04-10
First Post:
2005-09-04
Brief Title:
Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction Dose-responsive Clinical Pharmacology Study
Sponsor:
Mitsubishi Tanabe Pharma Corporation
Organization:
Mitsubishi Tanabe Pharma Corporation
Study Overview
Official Title:
Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction Clinical-pharmacological Dose-response Study
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sarpogrelate is an antiplatelet agent that decreases 5-hydroxytryptamine 5-HT levels in platelets via blockade of 5-HT2 receptors has been used in atherosclerotic peripheral arterial disease
The present double-blind controlled clinical pharmacology study was performed on 45 patients with cerebral infarction who were given 75 150 or 300 mg three times daily of sarpogrelate for 7 days in order to evaluate the dose-response relationship in terms of the precisely measured inhibition of platelet aggregation
The present double-blind controlled clinical pharmacology study was performed on 45 patients with cerebral infarction who were given 75 150 or 300 mg three times daily of sarpogrelate for 7 days in order to evaluate the dose-response relationship in terms of the precisely measured inhibition of platelet aggregation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None